SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?


To: LoLoLoLita who wrote (3776)5/1/1998 5:13:00 PM
From: Dauntless  Read Replies (1) | Respond to of 7041
 
Thread - HVSF press release

biz.yahoo.com



To: LoLoLoLita who wrote (3776)5/1/1998 5:21:00 PM
From: Tokyo VD  Respond to of 7041
 
David,

Just an FYI, I believe pulses and orthostatic blood pressures were measured periodically during the hour after dosing. The outcomes are unknown, but published information states that each phase III trial experienced a 20% drop-out rate (probably due to a variety of reasons). Just how many suffered from tachycardic or hypotensive effects from the medication is the $64,000 question?

Tokyo